Insight Molecular Diagnostics (IMDX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Insight Molecular Diagnostics (IMDX) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.03 of bullish evidence against -0.39 bearish.

Insight Molecular Diagnostics last closed at $3.67, +6.69% on the session.

Against the IVW growth benchmark the position is +5.77% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

13 graded predictions for IMDX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Insight Molecular Diagnostics in the 98th percentile on return on equity, where 100 is best.

Insight Molecular Diagnostics is classified under Health Care / Biotechnology, with a market capitalisation of $112.57M.

StockMap tracks Insight Molecular Diagnostics as the 257th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Insight Molecular Diagnostics ranks 287th of 344 in the group, against a group median of -0.21.